Bruker (NASDAQ:BRKR) Stock Gets Downgrade from Wall Street Zen

Bruker (NASDAQ:BRKR – Get Free Report) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.

BRKR has been the topic of several other reports. JPMorgan Chase & Co. cut Bruker from an “overweight” rating to a “neutral” rating and set a $60.00 target price on the stock. in a report on Wednesday, October 14th. The Goldman Sachs Group raised Bruker from a “strong sell” rating to a “strong-buy” rating in a report on Monday, September 21st. Citigroup lifted their price objective on Bruker from $53.00 to $64.00 and gave the stock a “hold” rating in a research report on Thursday, November 5th. Royal Bank Of Canada began coverage on Bruker in a research note on Friday. They set a “sector perform” rating and a $66.00 price objective on the stock. Finally, Stifel Nicolaus set a $50.00 target price on Bruker in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $61.00.

View Our Latest Research Report on Bruker

Bruker Stock Performance

BRKR opened at $56.46 on Friday. Bruker has a twelve month low of $32.37 and a twelve month high of $68.98. The firm has a market capitalization of $8.62 billion, a PE ratio of -51.33, a PEG ratio of 1.76 and a beta of 1.26. The company has a current ratio of 1.84, a quick ratio of 0.90 and a debt-to-equity ratio of 0.74. The firm’s 50-day moving average price is $59.99 and its 200 day moving average price is $51.31.

Bruker (NASDAQ:BRKR – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.14. The company had revenue of $874.00 million during the quarter, compared to the consensus estimate of $865.16 million. Bruker had a negative net margin of 3.82% and a positive return on equity of 13.76%. Bruker’s quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.45 EPS. As a group, sell-side analysts expect that Bruker will post 2.13 EPS for the current fiscal year.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total value of $105,740.00. Following the transaction, the vice president owned 134,806 shares of the company’s stock, valued at $7,127,193.22. This represents a 1.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 27.20% of the stock is currently owned by company insiders.

Institutional Trading of Bruker

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Essential Partners LLC purchased a new stake in Bruker in the 1st quarter valued at about $36,000. Global Retirement Partners LLC purchased a new position in Bruker during the second quarter worth about $38,000. Provenance Wealth Advisors LLC purchased a new position in Bruker during the third quarter worth about $52,000. EverSource Wealth Advisors LLC boosted its stake in Bruker by 532.9% during the first quarter. EverSource Wealth Advisors LLC now owns 1,500 shares of the medical research company’s stock worth $54,000 after buying an additional 1,263 shares during the period. Finally, Root Financial Partners LLC acquired a new stake in shares of Bruker during the third quarter valued at about $57,000. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Company Profile

(Get Free Report)

Bruker develops and manufactures scientific instruments and analytical technologies used to study biological, chemical and physical materials. Its products support research and testing in areas including life sciences, pharmaceuticals, biotechnology, materials science, chemicals and clinical diagnostics. The company’s offerings include nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray and microscopy instruments, and infrared and Raman spectroscopy solutions.

Recommended Stories

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.